Allogene Therapeutics Inc (NAS:ALLO)
$ 2.14 -0.05 (-2.28%) Market Cap: 459.18 Mil Enterprise Value: 269.53 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 37/100

Q4 2019 Allogene Therapeutics Inc Earnings Call Transcript

Feb 27, 2020 / 01:30PM GMT
Release Date Price: $25.92 (+1.85%)
Operator

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Allogene Therapeutics Fourth Quarter 2019 Conference Call. (Operator Instructions) Please be aware that today's conference call is being recorded.

I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.

Christine Cassiano
Allogene Therapeutics, Inc. - Chief Communications Officer

Thank you, operator, and good morning. Before market opened today, Allogene issued a press release that provides a corporate update and financial results for the fourth quarter and full year ended December 31, 2019. This press release is available on our website at www.allogene.com. We remind listeners that today's call is being webcast on our website and will be available for replay. Joining me on the call today are Dr. David Chang, President and Chief Executive Officer; Dr. Rafael Amado, Executive Vice President of Research and Development and Chief Medical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot